Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal

May 5, 2026

Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.

Cancer

Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal

May 4, 2026

By Karen Carey

No Comments

Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal

April 30, 2026

By Karen Carey

No Comments

Infection

Huahui Health describes new compounds for hepatitis B virus infection

Oct. 3, 2023

Huahui Health Ltd. has identified compounds reported to be useful for the treatment of hepatitis B virus infections.

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Selection Therapeutics identifies new Kv1.3 blockers

BioWorld Science

Selection Therapeutics GmbH has discovered new potassium voltage-gated channel subfamily A member 3 (KCNA3; Kv1.3) blockers potentially useful for the treatment...

Ignis Therapeutics synthesizes new muscarinic M4 receptor PAMs

BioWorld Science

Ignis Therapeutics (Suzhou) Co. Ltd. has patented new muscarinic M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of...